Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of December 2025. The filing details a specific share repurchase executed on November 28, 2025, acting through BNP Paribas SA as the broker. The Company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share buybacks rather than operational financial performance. Key metrics for the reported transaction include:
- Date of Purchase: November 28, 2025
- Shares Purchased: 250,000 ordinary shares of 31½ pence each
- Price Range: Lowest 1,786.00p; Highest 1,809.50p
- Volume-Weighted Average Price (VWAP): 1,799.00p
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
- Treasury Share Holdings: 236,608,577 shares (post-transaction)
- Shares in Issue: 4,078,825,107 (excluding Treasury shares)
- Treasury Voting Rights: 5.80% of total voting rights
Since the commencement of the current buyback programme on September 30, 2025, the Company has purchased an aggregate of 11,143,733 ordinary shares.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares held by the Company. The filing does not provide comparative financial data (e.g., revenue, profit, or cash flow) against prior periods, as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The Company confirms the purchase was part of an existing buyback programme effected pursuant to a non-discretionary agreement announced on September 30, 2025. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's 2024 Annual Report on Form 20-F and Q3 2025 Results. No new guidance or outlook was provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares in issue (4,078,825,107) for accurate calculation of ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 5.80% voting rights held in treasury to assess potential dilution or control implications.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining capacity of the current buyback programme.
- Check the 2024 Form 20-F and Q3 2025 Results for the full list of risk factors referenced in the cautionary statement.